In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post (Part I), we provide a 2021 year in review update on mRNA pioneers Moderna, BioNTech and CureVac, and in Part II, we profile Sanofi and other companies in the mRNA space and offer additional conclusions and outlook for 2022 and beyond.
Business
- Patent Licensing is a Risky Business: Let the Market Strike the Balance
- mRNA IP and Competitive Landscape: 2021 in Review – Part I, Update on Moderna, BioNTech, and CureVac
- Collaborative Patenting: The Future of IP and Innovation
- Machine Learning Models and the Legal Need for Editability: Surveying the Pitfalls (Part II)
- As Policymakers Say They Want to Rein in Big Tech, Others Seek to Give It Even More Power
Recent Posts
- Tillis to Garland/ Kanter: Pursuit of New Draft Policy on SEPs Shows a ‘Failure of innovation Leadership’
- Knowledge Ecology International’s New March-In Petition is Déjà vu All Over Again – With One Twist
- Property Rights Groups Urge Garland and Kanter to Withdraw ‘Misguided’ Policy Statement on SEPs Subject to FRAND
- CAFC Nixes District Court Claim Construction in Win for Firearms Patent Owner
- Tips for Litigating Multiple Simultaneous Patent Infringement Investigations at the ITC